Early recognition of patients at risk for Lynch syndrome is critical but often difficult. Recently, a predictive algorithm-the PREMM 1,2 model-has been developed to quantify the risk of carrying a germline mutation in the mismatch repair (MMR) genes MLH1 and MSH2. However, the model's performance in an unselected, population-based colorectal cancer population as well as its performance in combination with tumor MMR testing are unknown. Methods: We included all colorectal cancer cases from the EPI-COLON study, a prospective, multicenter, population-based cohort (n ‫؍‬ 1222). All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH2, and those with MMR deficiency (n ‫؍‬ 91) underwent tumor BRAF V600E mutation analysis and MLH1/MSH2 germline testing. Results: The PREMM 1,2 model with a >5% cut-off had a sensitivity, specificity, and positive predictive value (PPV) of 100%, 68%, and 2%, respectively. The use of a higher PREMM 1,2 cut-off provided a higher specificity and PPV, at expense of a lower sensitivity. The combination of a >5% cut-off with tumor MMR testing maintained 100% sensitivity with an increased specificity (97%) and PPV (21%). The PPV of a PREMM 1,2 score >20% alone (16%) approached the PPV obtained with PREMM 1,2 score >5% combined with tumor MMR testing. In addition, a PREMM 1,2 score of <5% was associated with a high likelihood of a BRAF V600E mutation. Conclusions: The PREMM 1,2 model is useful to identify MLH1/MSH2 mutation carriers among unselected colorectal cancer patients. Quantitative assessment of the genetic risk might be useful to decide on subsequent tumor MMR and germline testing.
Background & Aims:
Early recognition of patients at risk for Lynch syndrome is critical but often difficult. Recently, a predictive algorithm-the PREMM 1,2 model-has been developed to quantify the risk of carrying a germline mutation in the mismatch repair (MMR) genes MLH1 and MSH2. However, the model's performance in an unselected, population-based colorectal cancer population as well as its performance in combination with tumor MMR testing are unknown. Methods: We included all colorectal cancer cases from the EPI-COLON study, a prospective, multicenter, population-based cohort (n ‫؍‬ 1222). All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH2, and those with MMR deficiency (n ‫؍‬ 91) underwent tumor BRAF V600E mutation analysis and MLH1/MSH2 germline testing. Results: The PREMM 1,2 model with a >5% cut-off had a sensitivity, specificity, and positive predictive value (PPV) of 100%, 68%, and 2%, respectively. The use of a higher PREMM 1,2 cut-off provided a higher specificity and PPV, at expense of a lower sensitivity. The combination of a >5% cut-off with tumor MMR testing maintained 100% sensitivity with an increased specificity (97%) and PPV (21%). The PPV of a PREMM 1,2 score >20% alone (16%) approached the PPV obtained with PREMM 1,2 score >5% combined with tumor MMR testing. In addition, a PREMM 1,2 score of <5% was associated with a high likelihood of a BRAF V600E mutation. Conclusions: The PREMM 1,2 model is useful to identify MLH1/MSH2 mutation carriers among unselected colorectal cancer patients. Quantitative assessment of the genetic risk might be useful to decide on subsequent tumor MMR and germline testing. L ynch syndrome, also called hereditary nonpolyposis colorectal cancer, is the most common form of hereditary colorectal cancer (CRC), accounting for 1% to 5% of all colorectal malignancies. [1] [2] [3] It is characterized by early onset of CRC and other adenocarcinomas, predominantly endometrial cancer. The syndrome is inherited in an autosomal dominant pattern with variable penetrance and occurs as a consequence of germline mutations in the mismatch repair (MMR) system, 4 mainly in MLH1 and MSH2 (Ͼ90% of cases) 1 but also in MSH6 5 and PMS2. 6 The abnormal function of these genes leads to the accumulation of errors during DNA replication, particularly in repetitive sequences (microsatellites). As a result, tumors in patients with Lynch syndrome characteristically demonstrate microsatellite instability (MSI) 7 as well as loss of protein expression corresponding to the mutated gene. 8 The heterogeneity of Lynch syndrome complicates early recognition, which is critical and often not straightforward. The diagnostic criteria continue to evolve as understanding and characterization of this disorder improve. Indeed, identification of Lynch syndrome can be done by tumor MMR screening using MSI testing and/or immunostaining, in combination or not with clinical criteria. At present, the most widely accepted strategy relies on tumor molecular analysis in patients fulfilling the revised Bethesda guidelines. 7 Nevertheless, as in hereditary breast-ovarian cancer syndrome in the past, 9, 10 Lynch syndrome identification is moving toward more refined algorithms and multivariable models that com-bine personal and familial data to obtain a quantitative estimation of the risk. [11] [12] [13] [14] The PREMM 1,2 model 11 is a recently developed Webbased logistic regression model that predicts the likelihood of germline mutations in the MLH1 and MSH2 genes on the basis of personal and family history of individuals. It was developed in a large and diverse cohort of probands undergoing genetic testing on the basis of their clinical history. Whereas the model accurately discriminates gene mutation carriers in this subset of individuals at moderate to high risk for Lynch syndrome, 11 its usefulness in an unselected CRC population is unknown. Furthermore, efficacy of the PREMM 1,2 model in combination with tumor MMR testing has not yet been assessed.
Using data from the EPICOLON study 15, 16 -a prospective, multicenter, population-based cohort collected to establish the incidence and characteristics of hereditary and familial CRC forms in Spain-we assessed the efficacy of the PREMM 1,2 model, in combination or not with tumor MMR testing, for the identification of MLH1 and MHS2 gene mutation carriers among unselected CRC patients.
Materials and Methods Patients
Between November 2000 and October 2001, all newly diagnosed CRC patients in 25 hospitals were included in the EPICOLON study. 15, 16 Exclusion criteria were familial adenomatous polyposis, personal history of inflammatory bowel disease, and patient or family refusal to participate in the study. The study was approved by the institutional ethics committee of each participating hospital, and written informed consent was obtained from all patients.
Demographic, clinical, and tumor-related characteristics of probands, as well as a detailed family history were obtained using a pre-established questionnaire. Pedigrees were traced backward and laterally as far as possible, or at least up to second-degree relatives, in terms of cancer history. Age at cancer diagnosis, type, location, and tumor stage of the neoplasm and current status were recorded for each affected family member. 15, 16 
Tumor Microsatellite Instability Analysis and Immunostaining
Tissue samples from tumor and normal colonic mucosa were obtained from each patient, immediately frozen in liquid nitrogen, and stored at Ϫ70°C until use. In cases where no frozen tissue was available, formalinfixed, paraffin-embedded samples were used. Genomic DNA was isolated using the QiaAmp Tissue Kit (Qiagen, Courtaboeuf, France).
Microsatellite instability testing and immunostaining for MLH1 and MSH2 were performed in all patients regardless of age, personal or family history, and tumor characteristics. In addition, in those patients with a PREMM 1,2 score Ն20%, immunostaining for MSH6 and PMS2 was also performed. Paraffin-embedded sections were immunostained with antibodies against mismatch repair proteins (anti-MSH2, Oncogene Research Products, Boston, MA; anti-MLH1, PharMingen, San Diego, CA; anti-MSH6, BD Transduction Laboratories; anti-PMS2, PharMingen), as described elsewhere. 15 Tumor cells were judged to be negative for protein expression only if they lacked staining in a sample in which normal colonocytes and stroma cells were stained. If no immunostaining of normal tissue could be demonstrated, the results were considered ambiguous.
Microsatellite status was assessed using the 5-marker panel proposed by the National Cancer Institute, as described elsewhere. 15, 17, 18 Tumors were classified as stable if none of the markers showed instability. Tumors with 2 or more unstable markers were classified as high level MSI (MSI-H) and tumors with 1 unstable marker were classified as low-level MSI (MSI-L).
Germline MLH1/MSH2 Mutation Analysis
Patients found to have tumors with MMR deficiency (demonstrated by either MSI-H and/or lack of protein expression) underwent MSH2/MLH1 germline genetic testing. Moreover, all patients with a PREMM 1,2 score Ն20% with MMR-proficient tumors also underwent genetic testing.
Germline mutational analysis was performed by both multiple ligation probe amplification (MLPA) analysis and sequencing, as described elsewhere. 15 
Tumor BRAF V600E Mutation Analysis
Tumor BRAF V600E mutation analysis was performed in all patients with MSI (high and low) and/or lack of MLH1/MSH2 protein expression by direct sequencing in tumor DNA, as described elsewhere. 19 
Application of the PREMM 1,2 Model
The PREMM 1,2 model is a clinical model created to predict the likelihood of finding a MLH1 or MSH2 mutation in at-risk individuals. 11 The original study analyzed MLH1/MSH2 mutation prevalence in a large cohort of patients undergoing genetic testing at Myriad Genetic Laboratories Inc (Salt Lake City, UT). A multivariable model using logistic regression and including variables related to the proband and relatives was developed. The prediction rule is available as a Web-based tool at the Dana-Farber Cancer Institute web site (http:// www.dfci.org/premm). We calculated the PREMM 1,2 score for each patient included in the study using the SPSS V11.0 software package (SPSS Inc, Chicago, IL).
Statistical Analysis
Sensitivity, specificity, and positive predictive value (PPV) of the PREMM 1,2 model, either alone or in combination with tumor MMR testing, were calculated with respect to the presence of MLH1/MSH2 germline mutations. These performance characteristics depend on the cut-off used for the predicted risk of mutation, and we therefore arbitrarily evaluated the following cut-off levels: Ͻ5%, Ն5%, Ն10%, Ն20%, and Ն40%. Ninety-five percent binomial confidence intervals were calculated on the basis of the Adjusted Wald method. 20 Continuous variables were expressed as mean Ϯ standard deviation and compared by the Student t test. Categorical variables were compared by the 2 test, applying the Yates correction when needed.
All P values were two sided. A P value of less than .05 was considered to indicate a statistically significant difference. All calculations were performed using the 11.0 SPSS software package (SPSS Inc).
Results

Characteristics of the Patients
During the study period, 1222 patients with pathologically confirmed colorectal adenocarcinoma were diagnosed and included in the EPICOLON project. Demographic, clinical, and tumor-related characteristics of patients included in the study are summarized in Table 1 .
One hundred eleven (9.1%) patients showed tumor MSI, 83 of them (6.8%) were MSI-H and 28 (2.3%) were MSI-L. Likewise, 81 (6.6%) patients had a tumor with loss of protein expression in either MLH1 (60 cases) or MSH2 (21 cases). No patients with tumors that were MSI-L had lack of MMR protein expression. However, expression of both proteins was retained in 10 tumors with MSI-H, whereas loss of MLH1 or MSH2 expression was found in 8 patients whose tumor did not show MSI. Overall, 91 (7.4%) patients were found to have a tumor demonstrating MMR deficiency (defined as MSI-H and/or loss of MLH1 or MSH2 expression).
BRAF V600E mutation was detected in 20 of 83 (24.1%) MSI-H tumors and in 18 of 60 (30%) tumors exhibiting loss of MLH1 expression. In addition, only 2 of 28 (7.1%) MSI-L tumors showed the BRAF V600E mutation, whereas it was not observed in any tumor with loss of MSH2 expression.
Germline genetic testing identified 8 (0.7%) unambiguous mutations in either MSH2 (5 cases) or MLH1 (3 cases) genes.
Efficacy of the PREMM 1,2 Model for the Identification of MLH1/MSH2 Gene Carriers
The distribution according to the PREMM 1,2 predicted likelihood of carrying a MLH1/MSH2 germline mutation in the cohort was: Ͻ5%, 826 (68%); 5-9%, 266 (22%); 10 -19%, 98 (8%); 20 -29%, 23 (2%); and Ͼ40%, 9 (0.7%).
We first evaluated the PREMM 1,2 model for its ability to identify MLH1/MSH2 mutation carriers within the large cohort of CRC patients. Performance characteristics of the PREMM 1,2 model for the identification of MLH1/ MSH2 gene carriers depended on the cut-off used for the predicted risk of mutation (Table 2) . Using a cut-off of 
Ն5%
, the model had a sensitivity of 100%; therefore, no mutation carriers would be missed if molecular evaluation was restricted to individuals with a PREMM 1,2 score of Ն5%. Using higher cut-offs of 10%, 20%, and 40% led to a progressive loss of sensitivity (75%, 62.5%, and 25%, respectively). As expected, specificity increased with higher cut-offs and ranged from 68% with a 5% cut-off to 99.4% with a 40% cut-off. Positive predictive values of different cut-offs for the PREMM 1,2 model are depicted in Figure 1 .
Use of the PREMM 1,2 Model in Combination With Tumor MMR Testing
The addition of tumor MMR testing, either by MSI analysis or immunostaining, to the PREMM 1,2 model enhanced its performance by improving both specificity and PPV (Table 2) . A PREMM 1,2 score of Ն5% in combination with abnormal MMR testing was associated with a sensitivity of 100%, specificity of 97.4%, and PPV of 20.5%. The maximum PPV (36%) was achieved using a PREMM 1,2 score of Ն20% in combination with an abnormal tumor MMR result. The incremental gain obtained by the addition of MSI/immunohistochemistry testing was less at higher PREMM 1,2 cut-off values; at a PREMM 1,2 cut-off of 40%, the addition of MSI/immunohistochemistry testing did not lead to an improvement in specificity.
Characteristics of Patients With Low PREMM 1,2 Scores
The PREMM 1,2 score correlated not only with the prevalence of germline mutations but also with the frequency of MMR deficiency (Table 3) . Although 52 of 826 (6.3%) individuals with a PREMM 1,2 score Ͻ5% had a MSI-H tumor or showed loss of MLH1 and MSH2 on immunohistochemistry, none of them carried a germline MLH1/MSH2 mutation and 17 (33%) were associated with BRAF V600E mutation in the tumor (Table 3) . Interestingly, in patients with abnormal MMR tests, BRAF V600E mutation was significantly associated with a PREMM 1,2 score Ͻ5% (P ϭ .009). In fact, 17 of 20 (85%) patients with a MMR-deficient tumor associated with BRAF V600E mutation had a PREMM 1,2 score Ͻ5%, whereas none of the 14 patients with a MMR-deficient tumor and PREMM 1,2 score Ն20% showed this variant ( Table 3) . As recent data demonstrate that BRAF mutations are rare in Lynch syndrome tumors, the findings are consistent with the conclusion that a low PREMM 1,2 score indicates a low likelihood that a patient with CRC has Lynch syndrome.
Characteristics of Patients With High PREMM 1,2 Scores
When patients with a PREMM 1,2 score Ն20% were stratified according to their MMR status (Table 4) , patients with MMR-deficient tumors differed from those with MMR proficiency in some clinical characteristics: they are more likely women (P ϭ .02), have a lower prevalence of previous or synchronous adenomas (P ϭ .002), a higher prevalence of endometrial cancer (P ϭ .003), more first-degree relatives with CRC (P ϭ .01), and more second-degree relatives with endometrial cancer (P ϭ .03). Therefore, a high PREMM 1,2 score in combination with MMR proficiency identified a significant group of families, recently characterized in our series, with a less penetrant cancer phenotype, 18 in line with a similar group with Amsterdam I criteria recently described as familial CRC type X syndrome. 21 We further examined potential etiologies of the CRC in the patients with high PREMM 1,2 scores based on their MSI status. Five of 14 (36%) patients with PREMM 1,2 score Ն20% and a MMR-deficient tumor carried a MLH1/ MSH2 germline mutation. We further investigated potential etiologies of the high PREMM 1,2 scores for the 9 individuals who were not found to carry germline MLH1/ MSH2 mutations by performing supplemental analyses of PMS2 and MSH6 immunostaining, and BRAF mutation analysis. In these nonmutation carriers, no BRAF mutation was found, and normal PMS2 and MSH6 protein expression was observed in all tumors.
To better characterize the subset of patients with a PREMM 1,2 score Ն20% and MMR-proficient tumors (n ϭ 18), MSH6 and PMS2 immunostaining and MLH1/ MSH2 germline gene testing were performed in all of them. With respect to immunostaining, normal MSH6 and PMS2 protein expression was observed in all tumors. Furthermore, MLH1/MSH2 gene testing did not show any deleterious mutations. Finally, we performed MYH analysis, and one patient was found to have a biallelic MYH mutation (G382D/Y165C) in a nested study performed in the EPICOLON cohort. 22 The patient was a 49 year-old-man with 2 synchronous CRCs and 25 synchronous adenomas and no family history of any neoplasia.
Discussion
Extensive knowledge now available about the Lynch syndrome has encouraged researchers to look for a systematic, quantitative, and objective approach to identify these patients. [11] [12] [13] 23 We recently developed the Webbased PREMM 1,2 model 11 on the basis of a logistic regression analysis from a large cohort of patients at risk for hereditary CRC who underwent genetic testing to quantify the relative importance of known clinical parameters in Lynch syndrome and predict the likelihood of carrying a mutation in the MLH1 and MSH2 genes. Although the model performed well among individuals at moderate risk for Lynch syndrome, its usefulness and performance in a nonselected, population-based cohort of CRC patients, either alone or in combination with tumor MMR testing, was unknown.
Our study of 1222 population-based CRC cases demonstrates that the PREMM 1,2 model constitutes a useful approach to identify MLH1/MSH2 gene mutation carriers among patients with CRC, either alone or in combination with MMR tumor testing. The quantitative assessment of the genetic risk obtained with the PREMM 1,2 model may drive subsequent decisions about molecular testing. Moreover, the combination with tumor MMR analysis identified a sizable subgroup of patients with a heterogeneous high CRC risk, potentially involving familial CRC type X syndrome, MYH-related cancer, and other, still unknown inherited disorders.
The first important finding is the demonstration that a PREMM 1,2 cut-off of Ն5% identified all MLH1 and MSH2 mutation carriers among unselected CRC patients. The use of a higher PREMM 1,2 cut-off provided a higher specificity and PPV, at the expense of a lower sensitivity. The negative predictive value of a PREMM 1,2 score Ͻ5% was 100%, thus reinforcing the consistency of this cut-off point. Therefore, for the clinician in general practice, whose first decision point is to see if a patient with CRC needs further molecular evaluation for Lynch Syndrome, a score of Ͻ5% indicates that no further referral is likely to be necessary, whereas a score of Ն5% should lead to further molecular evaluation. The low specificity of a 5% cut-off for the presence of germline mutations necessitates further refinement of the likelihood of carrying a mutation prior to proceeding to genetic testing. Our data demonstrate that the combination of the PREMM 1,2 score with tumor MMR testing improved its specificity and PPV. Indeed, using a cut-off of Ն5%, the addition of an abnormal tumor MMR test result provided a specificity of 98% and a PPV of 21%. An interesting finding was that the PREMM 1,2 model, in combination with tumor MMR testing, is able to identify a subset of patients resembling the recently described familial CRC type X syndrome, 21 families who fulfill the Amsterdam I criteria without evidence of MMR deficiency. Individuals in such families have a lower incidence of CRC than those in families with Lynch syndrome, whereas incidence for other cancers may not be increased. The molecular etiology of this disorder remains unknown, with a probable heterogeneous genetic basis. In our study, patients with a PREMM 1,2 score Ն20% with MMR-proficient tumors had features similar to those with familial CRC type X syndrome 21 : weaker family history of CRC and other malignancies and lower incidence of endometrial cancer. Interestingly, one patient with a high PREMM 1,2 score and no evidence of MMR deficiency carried biallelic MYH mutations (Y165C/G382D).
We are aware that our study has some limitations. First, the relatively low number of patients with MLH1/ MSH2 mutations may constitute a potential drawback of the analysis, thus restraining the reliability of performance features. Second, the model does not account for MSH6 gene mutations, although it is certain that this gene is responsible for a small proportion of Lynch syndrome cases. Finally, genetic testing was mainly performed in those patients whose tumors showed MMR deficiency, even though it is unlikely that gene carriers were undetected when both MSI analysis and immunostaining were performed systematically. In addition, to exclude this possibility, patients with a PREMM 1,2 score Ն20% also underwent genetic testing.
In the last few years, there has been much interest in establishing different strategies to improve the identification of patients with Lynch syndrome. These approaches range from using clinical criteria alone (ie, the Amsterdam criteria) 24 to universal tumor molecular testing (ie, immunostaining) in any given CRC patient. 25 The current most widely accepted recommendation, on the basis of combination of the revised Bethesda guidelines and tumor MMR testing, 7 has been found to be an effective and efficient strategy for Lynch syndrome identification. 15 However, these clinical criteria have been criticized because of the use of broad and complex variables, which make them difficult to remember for a general health care professional, their low specificity, their inability to establish the likelihood of carrying a mutation in a given patient, and the difficulty of obtaining tumor samples from affected relatives to perform the MMR analyses. 23 A potential advantage of the PREMM 1,2 model with respect to the revised Bethesda guidelines relies on its quantitative nature. In fact, the model demonstrated a reasonable ability to discriminate among risk groups for probability of mutation with respect to the prevalence of mutations observed in the MLH1/MSH2 genes and the prevalence of MMR deficiency. The latter correlation was especially relevant given that a PREMM 1,2 score of Ͻ5% identified the subset of MMR-deficient tumors associated with the somatic BRAF V600E mutation, a circumstance consistent with what is seen in the sporadic CRC setting. 26 -28 Taking into account these results and the performance characteristics of the predicted model's risk groups, in combination or not with tumor MMR testing, we propose a strategy for MLH1/ MSH2 genetic testing in the clinical practice (Figure 2 ). According to this algorithm, a PREMM 1,2 score Ͻ5% could be considered a reliable cut-off to exclude those CRC patients who do not need further risk assessment because of its 100% negative predictive value for detecting germline MLH1/MSH2 gene mutations. In patients reaching this cut-off, further decisions could also be made on the basis of PREMM 1,2 score. In patients with a score between 5% and 19%, tumor MMR testing should be performed to achieve a reasonable PPV. Finally, considering the PPV of a PREMM 1,2 score Ն20% alone (16%) and the significant increase of the PPV at that point (Figure 1) , it seems reasonable to pursue direct genetic testing in patients reaching such a score, particularly if a tumor sample is not available. It is important to note, however, that in addition to the risk estimate generated from the predictive model, other important factors (ie, accessibility to genetic services, timelines of genetic information, insurance coverage, and availability of tumor block) may help determine which strategy is the most 
